Advanced in Medulloblastoma

Dr. Avanthi T. Shah

Pediatrics
Texas Health Resources
UT Southwestern - Pediatric Hematology-Oncology
5323 Harry Hines Blvd, 
Dallas, TX 
On Staff At
Advanced in Medulloblastoma
Texas Health Resources
UT Southwestern - Pediatric Hematology-Oncology
5323 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Avanthi Shah is a Pediatrics provider in Dallas, Texas. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. Her top areas of expertise are Osteosarcoma, Hepatoblastoma, Neuroblastoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 10 clinical trials in the study of Medulloblastoma.

Graduate Institution
UT Southwestern Medical Center - GME (2009)
Residency
UT Southwestern Medical Center - Pediatrics (2012)
Specialties
Pediatrics
Licenses
Pediatrics in CA
Fellowships
Stanford University School of Medicine - Ped Hem/Onc (2016)
Hospital Affiliations
Texas Health Dallas
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

UT Southwestern - Pediatric Hematology-Oncology
5323 Harry Hines Blvd, Dallas, TX 75390
Call: 214-648-3896

Additional Areas of Focus

Dr. Shah has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Procedure, Drug
Study Drugs: Larotrectinib, Larotrectinib Sulfate
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Procedure, Other, Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Procedure, Drug
Study Drug: Samotolisib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Drug: Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Other, Drug
Study Drug: Palbociclib
Study Phase: Phase 2
View 10 Less Clinical Trials

12 Total Publications

Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors.
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors.
Journal: Pediatric blood & cancer
Published: June 06, 2025
View All 12 Publications
Similar Doctors
Stanton C. Goldman
Advanced in Medulloblastoma
Dr. Stanton C. Goldman
Pediatrics
Advanced in Medulloblastoma
Dr. Stanton C. Goldman
Pediatrics

Texas Oncology - Medical City Dallas

7777 Forest Ln, Ste D400, 
Dallas, TX 
 (1463.7 miles away)
972-566-6647
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stanton Goldman is a Pediatrics provider in Dallas, Texas. Dr. Goldman is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

Experienced in Medulloblastoma
Dr. Ksenya Shliakhtsitsava
Pediatrics
Experienced in Medulloblastoma
Dr. Ksenya Shliakhtsitsava
Pediatrics

UT Southwestern - Pediatric Hematology/Oncology

5323 Harry Hines Blvd., 
Dallas, TX 
 (1462.4 miles away)
214-456-2382
Languages Spoken:
English
See accepted insurances

Ksenya Shliakhtsitsava is a Pediatrics provider in Dallas, Texas. Dr. Shliakhtsitsava is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hereditary Neuroblastoma, Neuroblastoma, and Hepatoblastoma.

Experienced in Medulloblastoma
Dr. Donald T. Beam
Pediatrics
Experienced in Medulloblastoma
Dr. Donald T. Beam
Pediatrics

Donald Timothy Beam, MD

1500 Cooper St, Fifth Fl, 
Fort Worth, TX 
 (1436.7 miles away)
682-885-4018
Languages Spoken:
English
See accepted insurances

Donald Beam is a Pediatrics provider in Fort Worth, Texas. Dr. Beam is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Acute Lymphoblastic Leukemia (ALL), Hereditary Spherocytosis, and Blood Clots.

VIEW MORE MEDULLOBLASTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
    • Distinguished
    • Hepatoblastoma
      Dr. Shah is
      Distinguished
      . Learn about Hepatoblastoma.
      See more Hepatoblastoma experts
    • Langerhans Cell Histiocytosis
      Dr. Shah is
      Distinguished
      . Learn about Langerhans Cell Histiocytosis.
      See more Langerhans Cell Histiocytosis experts
    • Neuroblastoma
      Dr. Shah is
      Distinguished
      . Learn about Neuroblastoma.
      See more Neuroblastoma experts
    • Osteosarcoma
      Dr. Shah is
      Distinguished
      . Learn about Osteosarcoma.
      See more Osteosarcoma experts
    • Advanced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Shah is
      Advanced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Adult Soft Tissue Sarcoma
      Dr. Shah is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Cantu Syndrome
      Dr. Shah is
      Advanced
      . Learn about Cantu Syndrome.
      See more Cantu Syndrome experts
    • Diencephalic Syndrome
      Dr. Shah is
      Advanced
      . Learn about Diencephalic Syndrome.
      See more Diencephalic Syndrome experts
    • Embryonal Tumor with Multilayered Rosettes
      Dr. Shah is
      Advanced
      . Learn about Embryonal Tumor with Multilayered Rosettes.
      See more Embryonal Tumor with Multilayered Rosettes experts
    • Ewing Sarcoma
      Dr. Shah is
      Advanced
      . Learn about Ewing Sarcoma.
      See more Ewing Sarcoma experts
    View All 25 Advanced Conditions
    • Experienced
    • Aase Syndrome
      Dr. Shah is
      Experienced
      . Learn about Aase Syndrome.
      See more Aase Syndrome experts
    • Adrenal Insufficiency Pediatric
      Dr. Shah is
      Experienced
      . Learn about Adrenal Insufficiency Pediatric.
      See more Adrenal Insufficiency Pediatric experts
    • Anemia
      Dr. Shah is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    • Beta Thalassemia
      Dr. Shah is
      Experienced
      . Learn about Beta Thalassemia.
      See more Beta Thalassemia experts
    • Bone Marrow Aspiration
      Dr. Shah is
      Experienced
      . Learn about Bone Marrow Aspiration.
      See more Bone Marrow Aspiration experts
    • Brain Stem Cancer
      Dr. Shah is
      Experienced
      . Learn about Brain Stem Cancer.
      See more Brain Stem Cancer experts
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.